Self-engineered binary nanoassembly enabling closed-loop glutathione depletion-amplified tumor ferroptosis

Area of Science:

• Biochemistry
• Nanotechnology
• Oncology

Background:

• Ferroptosis, an iron-dependent cell death, is a promising anticancer target.
• Tumor cells overproduce glutathione (GSH) to resist oxidative stress, hindering ferroptosis induction.
• Current strategies to reduce GSH production are insufficient for potent ferroptosis.

Purpose of the Study:

• To develop a novel nanotherapeutic strategy for amplified ferroptosis by targeting glutathione.
• To create a dual-drug nanoassembly for simultaneous intervention in GSH production and consumption.
• To investigate the efficacy of this strategy in a preclinical breast cancer model.

Main Methods:

• Fabrication of a carrier-free, PEGylated nanoassembly co-delivering Sorafenib (Sor) and gambogic acid (GA).
• In vitro and in vivo assessment of the nanoassembly's ability to induce closed-loop GSH depletion.
• Evaluation of the nanoassembly's antitumor activity in 4T1 breast tumor-bearing mice.

Main Results:

• The Sor/GA nanoassembly achieved tumor-specific co-delivery and release.
• A closed-loop GSH depletion was confirmed, resulting from Sor-induced production inhibition and GA-accelerated consumption.
• The nanoassembly demonstrated significant antitumor efficacy in vivo.

Conclusions:

• The developed dual-drug nanoassembly effectively induces ferroptosis via bidirectional GSH depletion.
• This nanotherapeutic approach offers a promising strategy for ferroptosis-driven cancer therapy.
• The study highlights the potential of combined production and consumption intervention for enhanced GSH depletion.